Innovative research methods for studying treatments for rare diseases: methodological review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine methods for generating evidence on health outcomes in patients with rare diseases. DESIGN: Methodological review of existing literature. SETTING: PubMed, Embase, and Academic Search Premier searched for articles describing innovative approaches to randomized trial design and analysis methods and methods for conducting observational research in patients with rare diseases. MAIN OUTCOME MEASURES: We assessed information related to the proposed methods, the specific rare disease being studied, and outcomes from the application of the methods. We summarize methods with respect to their advantages in studying health outcomes in rare diseases and provide examples of their application. RESULTS: We identified 46 articles that proposed or described methods for studying patient health outcomes in rare diseases. Articles covered a wide range of rare diseases and most (72%) were published in 2008 or later. We identified 16 research strategies for studying rare disease. Innovative clinical trial methods minimize sample size requirements (n=4) and maximize the proportion of patients who receive active treatment (n=2), strategies crucial to studying small populations of patients with limited treatment choices. No studies describing unique methods for conducting observational studies in patients with rare diseases were identified. CONCLUSIONS: Though numerous studies apply unique clinical trial designs and considerations to assess patient health outcomes in rare diseases, less attention has been paid to innovative methods for studying rare diseases using observational data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Cepeda, M. S. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg115 · Cited by 859
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482
Clinical research for rare disease: Opportunities, challenges, and solutions
Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., & Merkel, P. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.003 · Cited by 401
Clinical trials and rare diseases: A way out of a conundrum
Lilford, R. J., Thornton, J. G., & Braunholtz, D. (1995) · BMJ · doi:10.1136/bmj.311.7020.1621 · Cited by 237
Cited by
Röver, C., Knapp, G., & Friede, T. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0091-1 · Cited by 527
“Between-study heterogeneity then is anticipated, since the gathered pieces of evidence are likely to differ with respect to study designs, types of control groups or treatment allocation [17, 19, 20], Unkel S, Röver C, Stallard N, Benda N, Posch M, Zohar S, et al.”
BackgroundBeggs, A. H., Byrne, B. J., De Chastonay, S., Haselkorn, T., Hughes, I., James, E. S., Kuntz, N. L., Simon, J., Swanson, L. C., Yang, M. L., et al. (2018) · Muscle & Nerve · doi:10.1002/mus.26018 · Cited by 83
“Yes 22 (58) 30 (43) 52 (48) No 12 (32) 25 (36) 37 (34) Not documented 4 (11) 15 (21) 19 (18)”
Shimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
Nutritional interventions in primary mitochondrial disorders: Developing an evidence base
Camp, K. M., Krotoski, D., Parisi, M. A., Gwinn, K. A., Cohen, B. H., Cox, C. S., Enns, G. M., Falk, M. J., Goldstein, A. C., Gopal-Srivastava, R., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.09.002 · Cited by 59
Metadata
- Authors
- Gagne, J. J., Thompson, L., O'Keefe, K., & Kesselheim, A. S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-11-24
- Volume
- 349
- Issue
- nov24 15
- Pages
- g6802-g6802
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2102951373
- Cited by
- 192
- References
- 6
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.